Agio Pharmaceutical received an orphan drug designation to (PKR) activator from both the USFDA and EMA.
New York, U.S, 2020-Jul-17 — /EPR Network/ — Agios Pharmaceuticals, shared the proof of clinical concept that has been established based on preliminary analysis in the [read full press release…]